| Name | Title | Contact Details |
|---|
UCP of Suffolk is a Hauppauge, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
UConn Health is a vibrant, integrated academic medical center that is entering an era of unprecedented growth in all three areas of its mission: academics, research, and clinical care. UConn Health is at the center of Bioscience Connecticut, a bold plan introduced by Connecticut Governor Dannel P. Malloy and approved by the Connecticut General Assembly in 2011. The plan will strengthen Connecticut`s position as a national and global leader for bioscience innovation and improve access to quality health care for Connecticut citizens for generations to come. Based in Farmington, Connecticut – a popular suburb of the state`s capitol of Hartford – UConn Health is home to the School of Medicine, School of Dental Medicine, John Dempsey Hospital, UConn Medical Group, UConn Health Partners, University Dentists and a thriving research enterprise. With approximately 5,000 employees, UConn Health is a major economic driver in the region, generating nearly $1 billion annually in gross state product. It is closely linked with the University of Connecticut`s main campus in Storrs through multiple, cross-campus academic projects.
United Physicians, PC is a Bingham Farms, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
AHC is a Gainesville, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
DiagnoCure (TSX: CUR; OTCQX: DGCRF) is a life sciences corporation that develops and commercializes high-value cancer diagnostic tests that increase clinician and patient confidence in making critical treatment decisions. In 2008, the Corporation launched a colorectal cancer staging test through its U.S. CLIA laboratory. PrevistageTM GCC is currently available for licensing. The Corporation has granted a worldwide exclusive license on the diagnostic applications of its proprietary molecular biomarker PCA3 to Gen-Probe, now a wholly-owned subsidiary of Hologic Inc. Hologic Gen-Probe's PROGENSA® PCA3 prostate cancer test is commercialized in Europe under CE mark and is approved for commercialization in Canada and the United States.